The telomeric PARP, tankyrases, as targets for cancer therapy.
The requirement for the maintenance of telomeres by telomerase by most cancer cells for continued proliferation is a target in anticancer strategies. Tankyrases are poly(ADP-ribose) polymerases that enhance telomerase access to telomeres. Tankyrase 1 modulates telomerase inhibition in human cancer cells and is reviewed in this report as a potential telomere-directed anticancer target.
Seimiya
H
H
Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan. hseimiya@jfcr.or.jp
D000818:Animals; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D038501:Tankyrases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D019098:Telomerase / Q000037:antagonists & inhibitors; D016615:Telomere / Q000378:metabolism
D004791:Enzyme Inhibitors; D038501:Tankyrases; D019098:Telomerase